Interleukin-2 has no additional therapeutic efficacy in the retreatment of patients with chronic hepatitis C that had not responded to interferon-alpha plus ribavirin.
Barreiros
A P
AP
Schlaak
J F
JF
Gerken
G
G
Galle
P R
PR
Löhr
H F
HF
D018712:Analgesics, Non-Narcotic / Q000627:therapeutic use*; D000998:Antiviral Agents / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D019698:Hepatitis C, Chronic / Q000188:drug therapy*; D006801:Humans; D007376:Interleukin-2 / Q000627:therapeutic use*; D019233:Retreatment; D012254:Ribavirin / Q000627:therapeutic use*; D016896:Treatment Outcome
D018712:Analgesics, Non-Narcotic; D000998:Antiviral Agents; D007376:Interleukin-2; D012254:Ribavirin